Although the development of ALK tyrosine kinase inhibitors (TKIs) has revolutionized the treatment landscape for ALK-driven NSCLC patients, acquired resistance is inevitable and remains a critical unmet challenge [9, 10]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.